Valuation : CSPC Pharmaceutical Group Limited

Market Cap 111B 14.12B 12.15B 11.43B 10.44B 19.54B 1,333B 19.59B 135B 52.42B 684B 53.03B 51.87B 2,204B P/E 2026 *
10.9x
P/E 2027 * 16.2x
Enterprise Value 99.91B 12.74B 10.96B 10.32B 9.42B 17.63B 1,203B 17.68B 122B 47.3B 617B 47.85B 46.8B 1,988B EV / Sales 2026 *
2.59x
EV / Sales 2027 * 2.71x
Free-Float
67.42%
Yield 2026 *
4.66%
Yield 2027 * 3.74%
Sep. 01 CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China MT
Sep. 01 CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China MT
Sep. 01 CSPC Pharma Initiates Depression Drug Candidate Trial in China MT
Aug. 31 CSPC Pharma Begins Trial for Weight Management Drug in China MT
Aug. 31 Cspc Pharmaceutical Group Limited Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China CI
Aug. 28 Cspc Pharmaceutical Group Limited Initiates Phase Ii Clinical Trial of Syh2069 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China CI
Aug. 27 CSPC Pharma Gets Trial Nod for Weight Management Drug in China MT
Aug. 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For SYH2092 Injection CI
Aug. 26 CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA MT
Aug. 26 CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint MT
Aug. 26 CSPC Pharmaceutical Group Limited Reports Sys6090 Grants Fast Track Designation by U.S. Fda for Treatment of Patients with Mss/Pmmr Mcrc CI
Aug. 26 CSPC Pharmaceutical Group Limited Reports SYS6010 Meets Primary Endpoint In Phase III Clinical Study For EGFR-Mutated NSCLC CI
Aug. 25 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Recombinant Respiratory Syncytial Virus Vaccine SYS6057 In The U.S CI
1 day+0.78%
1 week+1.63%
Current month+4.82%
1 month+14.14%
3 months+33.77%
6 months+7.73%
Current year+14.89%
1 week 9.08
Extreme 9.08
9.76
1 month 8.21
Extreme 8.21
10.17
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.63
10 years 3.87
Extreme 3.86979
13.93
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 44 2024-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 56 2012-01-19
Director/Board Member 66 2012-12-20
Date Insider Type Main position Quantity % Market Cap. Importance
6/23/26 Other

Director

-700,000 0.0061%
5/29/26 Other

Chairman

9,402,000 0.0816%
5/28/26 Other

Chairman

40,000,000 0.3471%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+1.63%-10.57%+61.96% 14.12B
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.81%+1.15%+24.41%+52.22% 369.25B
Weighted average by Cap. -1.09%+0.55%+36.44%+66.21%

Financials

2026 *2027 *
Net sales 38.62B 4.93B 4.24B 3.99B 3.64B 6.81B 465B 6.83B 47.12B 18.29B 239B 18.5B 18.09B 769B 35.63B 4.54B 3.91B 3.68B 3.36B 6.29B 429B 6.3B 43.47B 16.87B 220B 17.06B 16.69B 709B
Net income 10.12B 1.29B 1.11B 1.04B 955M 1.79B 122B 1.79B 12.35B 4.79B 62.53B 4.85B 4.74B 201B 6.98B 890M 766M 721M 659M 1.23B 84.07B 1.24B 8.52B 3.31B 43.13B 3.34B 3.27B 139B
Net Debt -10.82B -1.38B -1.19B -1.12B -1.02B -1.91B -130B -1.91B -13.2B -5.12B -66.81B -5.18B -5.07B -215B -14.06B -1.79B -1.54B -1.45B -1.33B -2.48B -169B -2.49B -17.15B -6.66B -86.86B -6.73B -6.59B -280B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
18,626
Date Price Change Volume
26-09-04 HK$9.685 +0.78% 90,538,571
26-09-03 HK$9.610 +4.80% 134,922,261
26-09-02 HK$9.170 -0.65% 65,804,858
26-09-01 HK$9.230 -0.11% 59,562,215
26-08-31 HK$9.240 -3.04% 136,476,279
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
9.685HKD
Average target price
12.44HKD
Spread / Average Target
+28.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock